Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
NCT05858047 is registered in ClinicalTrials.gov with CSPC Ouyi Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 11, 2023
- Completion date
- February 21, 2024
- Enrollment
- 93 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
effects, drug side